Growing Demand for Innovative Anti-Itch Therapies Boosts U.S. Pruritus Treatment Market
Jun 2
<p>The <strong><a href="https://www.transparencymarketresearch.com/us-pruritus-treatment-market.html">U.S. pruritus treatment market</a></strong> was valued at US$ 5.1 billion in 2022 and is projected to surpass US$ 8.4 billion by 2031, driven by the rising prevalence of chronic skin conditions, increasing awareness regarding dermatological health, and growing demand for effective itch management therapies. The market is anticipated to expand at a CAGR of 5.6% from 2023 to 2031, supported by advancements in treatment options and increasing healthcare expenditure across the country.</p><p><strong>Download Sample of the Report: <a href="https://www.transparencymarketresearch.com/sample/sample.php?flag=S&amp;rep_id=85582">https://www.transparencymarketresearch.com/sample/sample.php?flag=S&amp;rep_id=85582</a> </strong></p><p>The pruritus treatment market in the U.S. is expected to witness significant growth in the next few years due to rise in prevalence of pruritus among the population. Surge in the geriatric population and increase in incidence of chronic diseases, such as diabetes and kidney diseases, are likely to propel market expansion. Furthermore, increase in awareness about the condition and availability of advanced treatment options, such as topical corticosteroids, antihistamines, and immunosuppressant, are projected to augment U.S. pruritus treatment industry growth in the next few years.</p><p>Rise in demand for over-the-counter (OTC) medications and surge in adoption of telemedicine are expected to offer lucrative opportunities to market players. Companies in the market are focusing on developing low cost and efficient OTC medications in order to increase market share and presence.</p><p><strong>Key Findings of the Market Report</strong></p><ul><li>Based on dosage form, demand for oral medications is expected to drive the market for pruritus treatment due to ease of administration and high patient compliance.</li><li>A greater emphasis on targeted biologics and small-molecule inhibitors is likely to create opportunities for pruritus therapies to thrive in the future.</li><li>Pruritus treatment products are in high demand across hospital pharmacies and specialized dermatology clinics.</li><li>The dominant market share of the U.S. pruritus treatment industry was held by the skin diseases segment in 2022, owing to high eczema and psoriasis prevalence.</li></ul><p><strong>U.S. Pruritus Treatment Market: Growth Drivers</strong></p><ul><li>The growing population of aging demographics largely drives the market growth of pruritus treatments. Physiological changes in aging skin, such as epidermal thinning and dryness, make older adults experience pruritus symptoms more frequently, increasing treatment demand.</li><li>As underlying conditions like chronic kidney disease (CKD) and cholestatic liver diseases become more common, specialized systemic itch treatments, including kappa opioid receptor agonists, will become more important. The therapeutics used enhance symptom relief and clinical efficiency.</li><li>Innovative dermatological research and pipeline clinical trials are being encouraged worldwide through private and public health funding. As a result, investors are investing in biotechnology, thereby increasing the demand for cutting-edge pruritus treatments.</li><li>Researchers are continually researching and developing neurological and immunological itch pathways, which leads to improved drug performance, cost-effectiveness, and safety. Material and molecular advancements are incorporated into the market as new formulations are developed.</li><li>A growing number of diagnosed cases of inflammatory disorders, such as atopic dermatitis and psoriasis, create a demand for high-performance therapies. In turn, this creates a need for more advanced biologic products. Targeted clinical options are becoming more popular as awareness of the psychological burden of chronic itch grows. Advanced therapies can enable faster symptom clearance and sustainable disease management.</li></ul><p><strong>U.S. Pruritus Treatment Market: Regional Landscape</strong></p><ul><li>The United States leads the North American theater and is expected to maintain its dominant position in the global pruritus treatment market. High healthcare expenditure is closely tied to the rapid adoption of premium biologic therapeutics in the United States. The U.S. has seen an increase in the number of novel drug approvals by the FDA, with many pharmaceutical companies planning to expand their localized dermatology pipelines.</li><li>Commercial insurance policies and government reimbursement incentives can also affect the demand for pruritus treatments. U.S. healthcare structures have promoted early access to precision medicines, which may drive the overall commercial demand for advanced therapies. The demand for targeted solutions is growing beyond basic topical over-the-counter creams to complex systemic regimens for end-stage renal disease (ESRD) patients. The use of innovative prescription formulations in these applications contributes significantly to market revenue overall.</li></ul><p> <strong>U.S. Pruritus Treatment Market: Key Players</strong></p><p>Major pruritus treatment manufacturers are using several organic and inorganic growth strategies to expand their market presence. Their production capability and clinical indications are being expanded to meet the increase in demand.</p><ul><li>Sanofi S.A.</li><li>Regeneron Pharmaceuticals, Inc.</li><li>Galderma S.A.</li><li>Pfizer Inc.</li><li>AbbVie Inc.</li><li>Eli Lilly and Company</li><li>Bristol-Myers Squibb Company</li><li>Cara Therapeutics, Inc.</li><li>Ipsen S.A.</li><li>Mirum Pharmaceuticals, Inc.</li></ul><p><strong>Key Developments</strong></p><ul><li>In March 2023, Ipsen announced the successful acquisition of Albireo Pharma, Inc., a leading innovator in bile-acid modulators, immediately strengthening its rare disease infrastructure and expanding its portfolio of adult and pediatric cholestatic liver disease pruritus treatments.</li><li>In March 2023, the U.S. Food and Drug Administration (FDA) accepted for review the supplemental Biologics License Application (sBLA) for Sanofi and Regeneron's Dupixent (dupilumab) to treat adults and adolescents with uncontrolled chronic spontaneous urticaria (CSU), accelerating the drug’s deployment into new therapeutic markets.</li></ul><p><strong>U.S. Pruritus Treatment Market: Segmentation</strong></p><p><strong>By Dosage Form</strong></p><ul><li>Oral</li><li>Topical</li><li>Parenteral</li></ul><p> </p><p><strong>By Pruritus Type</strong></p><ul><li>Skin Diseases</li><li>Atopic Dermatitis</li><li>Psoriasis</li><li>Allergic Contact Dermatitis</li><li>Urticaria</li><li>Others</li><li>Systemic Diseases</li><li>Chronic Kidney Disease-Associated Pruritus (CKD-aP)</li><li>Cholestatic Pruritus</li><li>Hematologic Pruritus</li><li>Endocrine Pruritus</li><li>Neurogenic/Neuropathic Pruritus</li><li>Psychogenic Pruritus</li></ul><p> </p><p><strong>By Product</strong></p><ul><li>Corticosteroids</li><li>Antihistamines</li><li>Biologics / Monoclonal Antibodies</li><li>JAK Inhibitors</li><li>Calcineurin Inhibitors</li><li>Topical Anesthetics & Counterirritants</li><li>Others</li></ul><p><strong>By Distribution Channel</strong></p><ul><li>Hospital Pharmacies</li><li>Retail Pharmacies</li><li>Online Pharmacies</li></ul><p><strong>By Region</strong></p><ul><li>Northeast</li><li>Midwest</li><li>South</li><li>West</li></ul><p><strong>Buy this Premium Research Report: <a href="https://www.transparencymarketresearch.com/checkout.php?rep_id=85582&amp;ltype=S">https://www.transparencymarketresearch.com/checkout.php?rep_id=85582&amp;ltype=S</a> </strong></p><p><strong>About Transparency Market Research</strong></p><p><strong>Transparency Market Research</strong>, a global <a href="https://www.globenewswire.com/Tracker?data=MKyRdE0P94ioyU9f_0pp_wK0uV5-pktG40_qdemb39yORO5ij1UiDsjS3kZVPgI-OU0u348INknIe5Axs0iEQkizjjMb2WGH24rFxKRmG66df6VI3JqcmmcboAodjufF"><strong>market research company</strong></a> registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information.</p><p>Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.</p><p><strong>Contact:</strong></p><p><strong>Abhishek Budholiya<br />Transparency Market Research Inc.<br /></strong>State Tower, 90 State Street, Suite 700,<br />Albany NY - 12207, United States<strong><br />Tel: </strong>+1-518-618-1030<br /><strong>USA – Canada Toll Free: </strong>866-552-3453<strong><br />Website: </strong><a href="https://www.transparencymarketresearch.com"><strong>https://www.transparencymarketresearch.com</strong></a><strong> </strong></p>